JP6387008B2 - インスリンアナローグダイマー - Google Patents

インスリンアナローグダイマー Download PDF

Info

Publication number
JP6387008B2
JP6387008B2 JP2015534623A JP2015534623A JP6387008B2 JP 6387008 B2 JP6387008 B2 JP 6387008B2 JP 2015534623 A JP2015534623 A JP 2015534623A JP 2015534623 A JP2015534623 A JP 2015534623A JP 6387008 B2 JP6387008 B2 JP 6387008B2
Authority
JP
Japan
Prior art keywords
chain
insulin
seq
alkyl
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015534623A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015532283A5 (enExample
JP2015532283A (ja
Inventor
リチャード ディー ディマルキ
リチャード ディー ディマルキ
ヤン チャオ
ヤン チャオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indiana University Research and Technology Corp
Original Assignee
Indiana University Research and Technology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indiana University Research and Technology Corp filed Critical Indiana University Research and Technology Corp
Publication of JP2015532283A publication Critical patent/JP2015532283A/ja
Publication of JP2015532283A5 publication Critical patent/JP2015532283A5/ja
Application granted granted Critical
Publication of JP6387008B2 publication Critical patent/JP6387008B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015534623A 2012-09-26 2013-09-25 インスリンアナローグダイマー Expired - Fee Related JP6387008B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261705834P 2012-09-26 2012-09-26
US61/705,834 2012-09-26
PCT/US2013/061676 WO2014052451A2 (en) 2012-09-26 2013-09-25 Insulin analog dimers

Publications (3)

Publication Number Publication Date
JP2015532283A JP2015532283A (ja) 2015-11-09
JP2015532283A5 JP2015532283A5 (enExample) 2016-11-10
JP6387008B2 true JP6387008B2 (ja) 2018-09-05

Family

ID=50389126

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015534623A Expired - Fee Related JP6387008B2 (ja) 2012-09-26 2013-09-25 インスリンアナローグダイマー

Country Status (7)

Country Link
US (1) US9593156B2 (enExample)
EP (2) EP2900255B1 (enExample)
JP (1) JP6387008B2 (enExample)
CN (2) CN108383902A (enExample)
AU (1) AU2013323669B2 (enExample)
CA (1) CA2886228A1 (enExample)
WO (1) WO2014052451A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2800173C (en) 2010-05-21 2019-05-14 Ulrik Nielsen Bi-specific fusion proteins
MX2015005662A (es) * 2012-11-05 2015-08-20 Univ Case Western Reserve Analogos de insulina de una sola cadena de larga accion.
CR20170208A (es) 2014-11-21 2017-07-17 Merck Sharp & Dohme Agonistas parciales del receptor de insulina
KR101669140B1 (ko) * 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
CN115960249A (zh) 2015-10-02 2023-04-14 银溪制药股份有限公司 用于组织修复的双特异性治疗性蛋白质
EP3448417B1 (en) * 2016-04-26 2025-11-12 Merck Sharp & Dohme LLC Insulin dimer-incretin conjugates
WO2017205191A1 (en) * 2016-05-24 2017-11-30 Merck Sharp & Dohme Corp. Insulin receptor partial agonists and glp-1 analogues
EP3463413A4 (en) * 2016-05-25 2020-03-04 Merck Sharp & Dohme Corp. INSULIN RECEPTOR PART AGONISTS
WO2017210077A1 (en) * 2016-06-02 2017-12-07 Indiana University Research And Technology Corporation Single chain insulin prodrugs
KR101887577B1 (ko) * 2016-10-19 2018-09-10 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
EP3645713A4 (en) * 2017-06-27 2021-06-30 Codexis, Inc. PENICILLIN-G ACYLASES
AU2018317810A1 (en) 2017-08-17 2020-03-19 Novo Nordisk A/S Novel acylated insulin analogues and uses thereof
EP3956355B1 (en) * 2019-04-19 2025-11-26 The Trustees of Indiana University Stabilization of prandial or basal insulin analogues by an internal diselenide bridge
US12435116B2 (en) 2019-10-16 2025-10-07 Clarence Hurt Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome
CN113801236A (zh) * 2020-06-11 2021-12-17 宁波鲲鹏生物科技有限公司 一种赖脯胰岛素的制备方法
CN113801235A (zh) * 2020-06-11 2021-12-17 宁波鲲鹏生物科技有限公司 一种赖脯胰岛素衍生物及其应用
EP4228675A1 (en) 2020-10-13 2023-08-23 Betavive Ltd. Method and compounds for treating diabetes and associated metabolic diseases
WO2022081794A1 (en) * 2020-10-15 2022-04-21 Tavotek Biotherapeutics (Hong Kong) Limited Shielded biologics with masking domains to shield antigen binding capability of biologics and uses thereof
MX2024004398A (es) * 2021-10-12 2024-07-09 Betavive Ltd Peptidos y fragmentos para tratar diabetes y enfermedades metabolicas asociadas.
WO2024137820A1 (en) * 2022-12-20 2024-06-27 The Board Of Trustees Of The Leland Stanford Junior University Insulin receptor antagonist

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3740385A (en) 1970-05-07 1973-06-19 M Ondetti N-terminal derivatives of secretin
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US4275152A (en) 1977-02-03 1981-06-23 Eastman Kodak Company Hydrolysis of protein-bound cholesterol esters
DK119785D0 (da) 1985-03-15 1985-03-15 Nordisk Gentofte Insulinpraeparat
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
PT83613B (en) 1985-10-28 1988-11-21 Lilly Co Eli Process for the selective chemical removal of a protein amino-terminal residue
US4741897A (en) 1986-07-08 1988-05-03 Baxter Travenol Thyroxine analogs and reagents for thyroid hormone assays
US4876242A (en) 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
GB8728561D0 (en) 1987-12-07 1988-01-13 Glaxo Group Ltd Chemical compounds
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US6225449B1 (en) 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
EP0469084B1 (en) 1989-04-20 1995-04-05 Mount Sinai School Of Medicine Of The City University Of New York Hepatospecific insulin analogues
US5268453A (en) 1991-08-08 1993-12-07 Scios Inc. Tissue-selective insulin analogs
FI953001A7 (fi) * 1992-12-18 1995-06-16 Lilly Co Eli Insuliinianalogeja
EP0688364A4 (en) 1993-03-09 1997-10-15 Abbott Lab ENZYMES PRODUCED BY GENETIC ENGINEERING AND CONJUGATES OF SAID ENZYMES FOR DIAGNOSTIC ANALYSIS
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US6476290B1 (en) 1995-04-19 2002-11-05 Dalhousie University Transgenic tilapia comprising a humanized insulin gene
EP0741188A3 (en) 1995-05-05 1999-07-14 Eli Lilly And Company Single chain insulin with high bioactivity
US6180767B1 (en) 1996-01-11 2001-01-30 Thomas Jefferson University Peptide nucleic acid conjugates
IL128828A0 (en) 1996-09-09 2000-01-31 Zealand Pharmaceuticals As Peptide prodrugs containing an alpha-hydroxy acid linker
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
EP1053752A1 (en) 1998-02-10 2000-11-22 Yoshitomi Pharmaceutical Industries, Ltd. Preparations with controlled release
SK12412000A3 (sk) 1998-02-23 2002-05-09 Neurocrine Biosciences, Inc. Metódy liečenia diabetu použitím peptidových analógov inzulínu
IL138214A0 (en) 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US20030236190A1 (en) 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
US6875741B2 (en) 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
GB2344287A (en) 1998-12-03 2000-06-07 Ferring Bv Controlled release pharmaceutical formulation
DE19908041A1 (de) 1999-02-24 2000-08-31 Hoecker Hartwig Kovalent verbrückte Insulindimere
WO2000058360A2 (en) 1999-03-29 2000-10-05 Uutech Limited Analogs of gastric inhibitory peptide and their use for treatment of diabetes
US6746853B1 (en) 1999-05-19 2004-06-08 Xencor, Inc. Proteins with insulin-like activity useful in the treatment of diabetes
AUPQ661800A0 (en) 2000-03-31 2000-05-04 Metabolic Pharmaceuticals Limited Insulin-potentiating compounds
JP2004509079A (ja) 2000-08-02 2004-03-25 セラテクノロジーズ・インコーポレーテッド 効力が増大した修飾生体ペプチド
AU2001284697A1 (en) 2000-08-04 2002-02-18 Dmi Biosciences, Inc. Method of synthesizing diketopiperazines
US7052686B2 (en) 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
KR100449454B1 (ko) 2000-10-02 2004-09-21 이현철 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터
KR101229995B1 (ko) 2000-12-11 2013-02-06 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
MXPA03009566A (es) 2001-04-19 2004-12-06 Scripps Research Inst Metodos y composicion para la produccion de pares trna-aminoaciltrna sintetasa ortogonales.
BR0215029A (pt) 2001-12-20 2005-12-20 Lilly Co Eli Molécula de insulina, uso da mesma, composição, uso desta, microcristal, processo para prepará-lo, uso deste, e, métodos para preparar uma molécula de insulina, para tratar hiperglicemia, e para tratar diabetes mellitus
FR2842209B1 (fr) 2002-07-09 2007-11-23 Nouvelle protease aspartique dite saspase et son utilisation dans le domaine cosmetique et therapeutique
ATE458534T1 (de) 2002-10-04 2010-03-15 Microchips Inc Medizinische vorrichtung zur gesteuerten arzneimittelverabreichung sowie herzüberwachung und/oder herzstimulation
WO2004067548A2 (en) 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
EP1626981A4 (en) 2003-03-04 2006-11-22 Biorexis Pharmaceutical Corp PROTEINS PROTECTED AGAINST DIPEPTIDYLPEPTIDASE
PL1605897T3 (pl) 2003-03-19 2012-12-31 Lilly Co Eli Związki będące połączeniem GLP-1 z poli(glikolem etylenowym)
EP1620118B1 (en) 2003-04-08 2014-06-18 Yeda Research And Development Co., Ltd. Reversible pegylated drugs
WO2005027978A2 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
WO2005035003A2 (en) 2003-09-22 2005-04-21 Dihedron Corporation Compositions and methods for increasing drug efficiency
PL2332968T3 (pl) 2003-11-05 2017-08-31 Dana-Farber Cancer Institute, Inc. Stabilizowane alfa-helikalne peptydy i ich zastosowania
EP1692168B1 (en) 2003-12-03 2011-07-20 Novo Nordisk A/S Single-chain insulin
EP1812082B1 (en) 2004-10-21 2013-08-14 IGF Oncology, LLC Toxins and radionuclides coupled to IGF-1 receptor ligands for the treatment of cancer
WO2006097521A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Pegylated single-chain insulin
US7521211B2 (en) * 2005-04-05 2009-04-21 Regeneron Pharmaceuticals, Inc IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof
WO2006113452A2 (en) 2005-04-13 2006-10-26 University Of Medicine And Dentistry Of New Jersey Glycoprotein hormone analogs
GB2427360A (en) * 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
US8304386B2 (en) 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
JP2009527526A (ja) 2006-02-21 2009-07-30 ノボ・ノルデイスク・エー／エス 単鎖インスリンのアナログとその製薬的製剤
EP1996224B1 (en) 2006-03-15 2012-11-07 Novo Nordisk A/S Mixtures of amylin and insulin
US9505823B2 (en) 2006-08-07 2016-11-29 TEV A Biopharmaceuticals USA, Inc. Albumin-insulin fusion proteins
CA2660835A1 (en) 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable propperties
CL2007002502A1 (es) 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
CA2663083A1 (en) 2006-09-08 2008-03-13 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
CA2683698C (en) 2007-04-19 2013-09-10 Hyun Hee Kwak A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
CN101157725B (zh) 2007-10-24 2012-07-25 中国药科大学 人胰岛素类似物的制备方法及用途
MX338336B (es) 2007-11-20 2016-04-07 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
AR063987A1 (es) 2007-11-27 2009-03-04 Segundo Mariano Aposito utilizable como cobertura temporal para el tratamiento de heridas y procesos para su fabricacion
WO2009099763A1 (en) 2008-01-30 2009-08-13 Indiana University Research And Technology Corporation Ester-based peptide prodrugs
JP5588354B2 (ja) 2008-02-01 2014-09-10 アセンディス ファーマ エー／エス 自己切断可能なリンカーを含むプロドラッグ
EP2356139A4 (en) 2008-07-23 2013-01-09 Harvard College LIGURE COMBINED POLYPEPTIDES
WO2010071807A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
JP5789515B2 (ja) 2008-12-19 2015-10-07 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン類似体
CN102300580A (zh) 2008-12-19 2011-12-28 印第安纳大学研究及科技有限公司 二肽连接的药剂
CA2744558A1 (en) * 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
EP2408470A4 (en) 2009-03-20 2012-08-29 Smartcells Inc SOLUBLE NONDEPOT INSULIN CONJUGATE AND ITS USE
MA33467B1 (fr) 2009-07-31 2012-07-03 Sanofi Aventis Deutschland Promédicaments comprenant un conjugué insuline-lieur
CN101993485B (zh) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 促胰岛素分泌肽类似物同源二聚体及其用途
CN103068842B (zh) * 2010-06-16 2016-10-19 印第安纳大学研究及科技有限公司 对胰岛素受体具有高活性的单链胰岛素激动剂
WO2011163462A2 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
US8778872B2 (en) 2010-06-24 2014-07-15 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
WO2011163460A1 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Yl-based insulin-like growth factors exhibiting high activity at the insulin receptor

Also Published As

Publication number Publication date
US9593156B2 (en) 2017-03-14
CN108383902A (zh) 2018-08-10
AU2013323669B2 (en) 2018-03-01
EP3395358B1 (en) 2019-11-06
CN104981251A (zh) 2015-10-14
US20150274802A1 (en) 2015-10-01
EP2900255B1 (en) 2019-01-30
WO2014052451A2 (en) 2014-04-03
AU2013323669A1 (en) 2015-03-26
CN104981251B (zh) 2018-03-20
EP2900255A4 (en) 2016-06-22
JP2015532283A (ja) 2015-11-09
WO2014052451A3 (en) 2014-06-19
EP2900255A2 (en) 2015-08-05
CA2886228A1 (en) 2014-04-03
EP3395358A1 (en) 2018-10-31

Similar Documents

Publication Publication Date Title
JP6387008B2 (ja) インスリンアナローグダイマー
JP5969469B2 (ja) インスリン受容体に対して高い活性を示す単鎖インスリンアゴニスト
JP6392123B2 (ja) 糖尿病治療のためのｃｔｐ系インスリンアナローグ
JP6538645B2 (ja) インスリン‐インクレチン複合物
JP6657230B2 (ja) インクレチン−インスリンコンジュゲート
WO2011159882A2 (en) Novel stabilized insulin agonists
CN107001441A (zh) 脂质化的基于酰胺的胰岛素前药

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160923

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160923

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170809

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171102

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180711

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180810

R150 Certificate of patent or registration of utility model

Ref document number: 6387008

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees